Premium
Combinational chemotherapy of L1210 and L1210/ARA‐C leukemia with 5‐AZA‐2′‐deoxycytidine and β‐2′‐deoxythioguanosine
Author(s) -
Momparler Richard L.,
Momparler Louise F.,
Samson Johanne
Publication year - 1982
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910300317
Subject(s) - l1210 cells , deoxycytidine kinase , deoxycytidine , leukemia , cytarabine , in vitro , in vivo , cytotoxic t cell , pharmacology , cancer research , chemotherapy , biology , chemistry , cytotoxicity , biochemistry , immunology , genetics , gemcitabine
The in vitro and in vivo antineoplastic activity of 5‐AZA‐2'‐deoxycytidine (5‐AZA‐CdR) and β‐2‐deoxythioguanosine (TGdR) on L1210 an L1210/ARA‐C (resistant to cytosine arabinoside) leukemic cells was investigated. 5‐AZA‐CdR was a very potent cytotoxic agent against the L1210 leukemic cells. This analogue was inactive against L1210/ARA‐C leukemic cells because these cells lack deoxycytidine kinase, the enzyme that converts 5‐AZA‐CdR to its active nucleotide form. TGdR was a potent cytotoxic agent to both L1210 and L1210/ARA‐C leukemic cells. In mice which were injected simultaneously with both L1210 and L1210/ARA‐C leukemic cells, the drug combination of 5‐AZA‐CdR plus TGdR had a very potent antineoplastic activity and producet long‐term survivors. Either agent alone did not produce any long‐term survivors in the mice with L1210 and L1210/ARA‐C leukemia. This experimental model indicates that 5‐AZA‐CdR plus TGdR is an interesting drug combination for the treatment of leukemia with drug‐resistant cells.